Riluzole

Generic Name: Riluzole

Brand Names: Exservan, Rilutek, Tiglutik, Riluzole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₅F_₃N_₂OS

CAS Number: 1744-22-5

Unique Ingredient Identifier: 7LJ087RS6F

Background: A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.

Indication: For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)

Associated Conditions: Amyotrophic Lateral Sclerosis (ALS)

Clinical Trials

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Phase 3

Recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Masitinib (6.0)
Drug: Riluzole
Drug: Masitinib (4.5)
Drug: Placebo

First Posted Date: 2017-04-25

Last Posted Date: 2023-04-18

Lead Sponsor: AB Science

Target Recruit Count: 495

Registration Number: NCT03127267

Locations: 🇺🇸
Johns Hopkins Medicine Brain Science Institute, Baltimore, Maryland, United States
🇧🇪
University Hospital Leuven (UZ Leuven), Leuven, Belgium
🇺🇦
Communal Non-Profit Enterprise of Lviv Regional Council, Lviv Regional Clinical Hospital, Neurological Department, Lviv, Ukraine

and more 53 locations

MIROCALS: Modifying Immune Response and OutComes in ALS

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole
Drug: 5% glucose water solution
Drug: IL-2

First Posted Date: 2017-02-01

Last Posted Date: 2022-04-11

Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Target Recruit Count: 304

Registration Number: NCT03039673

Locations: 🇫🇷
CHRU de Lille - Hôpital Roger Salengro, Lille, France
🇫🇷
CHU de Limoges - Hôpital Dupuytren, Limoges, France
🇫🇷
HCL - Hôpital Neurologique P. Wertheimer, Lyon, France

and more 14 locations

Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

Phase 2

Completed

Conditions: Social Anxiety Disorder
Performance Anxiety

Interventions: Drug: Placebo
Drug: BHV-0223

First Posted Date: 2017-01-11

Last Posted Date: 2021-05-20

Lead Sponsor: Yale University

Target Recruit Count: 22

Registration Number: NCT03017508

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States

Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition

Phase 2

Recruiting

Conditions: Spinal Cord Injury

Interventions: Drug: Placebo
Drug: Riluzole
Biological: Blood Samples

First Posted Date: 2016-08-09

Last Posted Date: 2023-04-21

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 90

Registration Number: NCT02859792

Locations: 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

Phase 4

Completed

Conditions: Inflammation
Fatigue

Interventions: Drug: Placebo
Drug: Riluzole

First Posted Date: 2016-06-13

Last Posted Date: 2021-04-14

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT02796755

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS

Not Applicable

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Riluzole
Drug: endocannabinoid palmitoylethanolamide (PEA)

First Posted Date: 2016-01-01

Last Posted Date: 2016-01-05

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 50

Registration Number: NCT02645461

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: Riluzole
Drug: Masitinib (4.5)
Drug: Masitinib (3.0)
Drug: Placebo

First Posted Date: 2015-10-28

Last Posted Date: 2023-09-29

Lead Sponsor: AB Science

Target Recruit Count: 394

Registration Number: NCT02588677

Locations: 🇪🇸
Hospital Carlos III, Madrid, Spain

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo (for MN-166)
Drug: MN-166
Drug: riluzole

First Posted Date: 2014-09-12

Last Posted Date: 2021-11-05

Lead Sponsor: MediciNova

Target Recruit Count: 70

Registration Number: NCT02238626

Locations: 🇺🇸
Carolinas Healthcare System, Dept. of Neurology, Charlotte, North Carolina, United States

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

Phase 1

Completed

Conditions: PTSD

Interventions: Drug: Placebo (for Riluzole)
Drug: Riluzole

First Posted Date: 2014-06-04

Last Posted Date: 2021-05-24

Lead Sponsor: Uniformed Services University of the Health Sciences

Target Recruit Count: 75

Registration Number: NCT02155829

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸
Syracuse VA Medical Center, Center for Integrated Healthcare (116C), Syracuse, New York, United States

Impact of Persistent Conductances on Motor Unit Firing in SCI

Not Applicable

Conditions: Chronic Spinal Cord Injury

Interventions: Drug: Memantine
Procedure: Therapeutic muscle stretching
Drug: sugar pill
Drug: Riluzole
Drug: Isradipine

First Posted Date: 2014-05-13

Last Posted Date: 2014-05-13

Lead Sponsor: Shirley Ryan AbilityLab

Target Recruit Count: 50

Registration Number: NCT02136823

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy